• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.

作者信息

Wan Eric Yuk Fai, Yan Vincent Ka Chun, Mok Anna Hoi Ying, Wong Ian Chi Kei, Chan Esther Wai Yin

机构信息

Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, and Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

出版信息

Ann Intern Med. 2023 Oct;176(10):eL230265. doi: 10.7326/L23-0265.

DOI:10.7326/L23-0265
PMID:37844307
Abstract
摘要

相似文献

1
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.莫努匹韦和奈玛特韦-利托那韦对COVID-19住院患者的疗效
Ann Intern Med. 2023 Oct;176(10):eL230265. doi: 10.7326/L23-0265.
2
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.莫努匹韦和奈玛特韦-利托那韦在 COVID-19 住院患者中的疗效：一项目标试验模拟研究。
Ann Intern Med. 2023 Apr;176(4):505-514. doi: 10.7326/M22-3057. Epub 2023 Mar 14.
3
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.确定并比较莫努匹拉韦和奈玛特韦-利托那韦对新冠病毒肺炎住院患者的实际疗效。
J Korean Med Sci. 2024 Feb 19;39(6):e52. doi: 10.3346/jkms.2024.39.e52.
4
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.莫努匹拉韦和奈玛特韦/利托那韦：新型可用的新冠病毒抗病毒药物选择
Acta Med Indones. 2022 Oct;54(4):638-644.
5
Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.在养老院居住的患者中，使用奈玛特韦/利托那韦和莫努匹韦治疗 COVID-19 的临床结果。
JAMA Netw Open. 2023 Apr 3;6(4):e2310887. doi: 10.1001/jamanetworkopen.2023.10887.
6
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.莫努匹拉韦和奈玛特韦-利托那韦对COVID-19住院患者的疗效
Ann Intern Med. 2023 Oct;176(10):eL230264. doi: 10.7326/L23-0264.
7
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.在欧洲血液系统恶性肿瘤高危COVID-19患者中，莫努匹韦与奈玛特韦/利托那韦的比较。来自EPICOVIDEHA注册研究的配对分析。
Int J Antimicrob Agents. 2023 Oct;62(4):106952. doi: 10.1016/j.ijantimicag.2023.106952. Epub 2023 Aug 13.
8
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.奥密克戎变异株流行期间，未住院的 2 型糖尿病合并 SARS-CoV-2 感染患者接受莫努匹韦或奈玛特韦/利托那韦治疗后的全因住院和死亡分析。
JAMA Netw Open. 2023 May 1;6(5):e2314393. doi: 10.1001/jamanetworkopen.2023.14393.
9
Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.奈玛特韦/利托那韦或莫努匹韦治疗后 COVID-19 反弹的临床特征：一项前瞻性队列研究。
Medicine (Baltimore). 2023 Sep 29;102(39):e35094. doi: 10.1097/MD.0000000000035094.
10
Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study.莫努匹韦和奈玛特韦/利托那韦与奥密克戎住院患者死亡率和脓毒症降低的关联：全港范围的研究。
Sci Rep. 2023 May 15;13(1):7832. doi: 10.1038/s41598-023-35068-w.

引用本文的文献

1
COVID-19 therapeutics.新型冠状病毒治疗药物。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0011923. doi: 10.1128/cmr.00119-23. Epub 2024 May 21.